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Abstract
Background: Recent renewed emphasis on the eradication of malaria has highlighted the need for more tools
with which to achieve this ambitious goal. One high priority area is the need to determine the gametocytocidal
activity of both currently used anti-malarial drugs and those in the development pipeline. However, testing the
activity of compounds against Plasmodium falciparum gametocytes is technically challenging both in vivo and in
vitro.
Methods: Here the use of a simple robust assay to screen a panel of currently used and experimental anti-malarial
drugs against mature P. falciparum gametocytes is described.
Results: Eight of 44 compounds tested reduced gametocyte viability by at least 50% and three showed IC50 values
in nM range.
Conclusions: There is a need to identify new compounds with activity against late stage gametocytes and the
information provided by this in vitro assay is a valuable first step, which can guide future clinical studies.
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Background
Gametocytes are the sexual stage of the malaria parasite,
which develop in red blood cells and are essential for
transmission to the mosquito vector. It has long been
recognized that patients treated for malaria should be
cleared of gametocytes in order to prevent them trans-
mitting the infection to others [1]. This is particularly
challenging in the case of Plasmodium falciparum infec-
tions as gametocytes of this species have a much longer
lifespan than asexual stages. Late-stage gametocytes
(stages IV-V) are more resistant to anti-malarial drugs
and metabolic inhibitors [2] than early-stage gameto-
cytes or asexual stage parasites. Primaquine is currently
the only licensed anti-malarial drug that is effective
against late stage P. falciparum gametocytes but has a
number of drawbacks including its propensity to cause
acute haemolysis in individuals with glucose-6-phos-
phate dehydrogenase (G6PD) deficiency.
With malaria eradication back on the global health
agenda there is renewed emphasis on the identification
of new and novel agents that can eliminate late-stage
gametocytes in the patient’s circulation and therefore
block transmission of the parasite from its human host
to the mosquito vector. However, evaluating the activity
of promising anti-malarial drugs against Plasmodium
gametocytes is difficult even in vitro. To this end a sim-
ple medium-high throughput assay suitable for assessing
the potential of new and novel anti-gametocyte drugs
has recently been described [3].
H e r eam o d i f i c a t i o no ft h i si n n o v a t i v ea s s a ys y s t e mi s
used to evaluate the activity of a panel of 44 compounds
(comprising currently used and experimental anti-malar-
ial drugs) against mature P. falciparum gametocytes.
Methods
Dixon et al. have previously reported the development
of an assay utilizing a green fluorescent protein chimera
of the early sexual blood stage protein Pfs16 as a marker
for commitment to gametocytogenesis [4]. This reporter
system allows accurate identification of gametocytes well
before they are morphologically distinguishable from
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numbers of pure gametocytes.
Production of late stage gametocytes
Mature stage V gametocytes were obtained as described
previously [3], briefly, 30 mL of synchronous ring stage
cultures of the transgenic parasite line 3D7GFP16B were
established at 1-2% parasitaemia. The parasites were
grown under standard conditions [5] through one com-
plete invasion cycle and gametocyte production induced
by the addition of conditioned media to trophozoite
stage parasites [6]. The parasites were grown through
one further invasion cycle and gametocytes were sepa-
rated from asexual parasites and uninfected red blood
cells using a modified Percoll step gradient [7]. These
gametocyte-enriched cultures were sorted and collected
using a BD FACSAria II cell sorter (BD Biosciences).
The gametocytes were sorted based on expression of the
GFP reporter gene to give only stage I/II gametocytes
which were matured to stage V in vitro under standard
culture conditions. This maturation takes between 5 and
7 days and was monitored daily by examination of
Giemsa stained thin smears.
Drug assay
Approximately 5,000 gametocytes were dispensed into
each well of a 96-well plate. The test compounds were
added to give a final volume of 100 μla n dt h ep l a t e
incubated at 37°C for 24 hours under standard culture
conditions. BacTiter-Glo reagents (Promega G8231)
were added to a final volume of 200 μla n dt h ea s s a y
read using a GloMax
® 96 Microplate Luminometer
[Cat.# E6501] with an integration constant of 0.5 sec-
onds. BacTitre-Glo is a homogenous ATP-based biolu-
minescent assay for detectinga n dq u a n t i f y i n gv i a b l e
microbial cell numbers. The assay uses a single reagent
t or e l e a s ea n dm e a s u r et h eA T P contained in the cells.
The presence of ATP indicates live cells and when com-
pared to a known standard can provide quantitative data
on the gametocytocidal effect of compounds.
All compounds were dissolved in DMSO and tested in
triplicate on three separate occasions at a final concen-
tration of 10 μM( 1 %D M S O ) .T h ea s s a yi n c l u d e da
positive control for gametocytocidal effect that consisted
of gametocytes lysed with H2O2 and a negative control
made of standard culture media with 1% DMSO (final
concentration of solvent in all samples tested).
Data analysis
Read-outs from drug-treated wells were compared to
those of control wells and percentage inhibition calcu-
lated. IC50 values were determined using Graphpad
Prism.
Results
A panel of 44 compounds, provided by the Medicines
for Malaria Venture, was made up of both currently
used and experimental anti-malarial drugs. All com-
pounds were tested at a single concentration of 10 μM
in a blinded study for activity against late stage P. falci-
parum gametocytes. Compounds were unblinded follow-
ing data analysis (Figure 1A).
Of the 44 compounds tested eight demonstrated a
reduction in ATP production greater than 50%, indicat-
ing that these compounds reduced gametocyte viability
by at least 50%. Methylene blue was the most active
compound, giving an 88% reduction in ATP production
compared to controls; a further seven compounds
showed inhibition of ATP production ranging from 57%
(hydroxychloroquine) to 66% (pyronaridine). Of the
remaining 39 compounds, several showed no inhibition
of ATP production, indicating they have no activity
against mature gametocytes; these include the currently
used anti-malarial drugs chloroquine, doxycyclin and
quinine.
Compounds which demonstrated a greater than 50%
reduction in ATP production also underwent dose
response testing in an 11-point dilution curve at con-
centrations ranging from 5 μMt o0 . 5n M .I C 50 values
were determined using Graphpad Prism and are shown
in Figure 1B. Thiostrepton was excluded from this ana-
lysis due to insufficient compound for testing at a range
of concentrations.
Three compounds had IC50 values in the nM range;
methylene blue had the lowest at IC50 value at 12 nM,
and was followed by pyronaridine (280 nM) and penta-
midine (404 nM).
Discussion
Ideal drugs and combination therapies for malaria era-
dication campaigns should clear asexual parasitaemia,
reducing clinical symptoms as quickly as possible and
prevent transmission of the sexual stages. However,
gametocytes are refractory to most currently used
anti-malarials and this lack of drugs with activity
against late-stage P. falciparum gametocytes makes
identification of new compounds with such activity a
high priority. Indeed, the malERA Consultative Group
on Drugs [8] recently identified the need to determine
the gametocytocidal activity of both currently used
anti-malarial drugs and those in the development
pipeline as a high priority, alongside the need to
develop new drugs with the ability to kill or prevent
development of gametocytes.
Here a simple, rapid in vitro assay is used to under-
take a comprehensive study into the effect of currently
used and experimental anti-malarial drugs on late stage
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gametocyte viability by at least 50%. Three of these were
currently used anti-malarial drugs, hydroxychloroquine,
artesunate, pyronaridine and three were anti-malarial
drugs currently in the development pipeline: NPC1161B,
OZ277 and methylene blue. Two additional compounds,
pentamidine: an anti-microbial effective in treatment of
leishmaniasis and Trypanosoma brucei, and thiostrepton,
a complex natural product derived from Streptomyces
and mainly used in veterinary medicine, are unlikely to
be suitable for mass use as anti-gametocyte agents. The
finding, that artesunate has demonstrated activity
against mature stage gametocytes, confirms the findings
of other groups but this does not appear to translate
into a significant clinical effect against mature stage
gametocytes in patients [9]. The most likely explanation
is that in vitro testing cannot take into account in vivo
pharmacokinetics, and artesunate has a relatively short
half-life in vivo [ 1 0 ] .H o w e v e r ,t h ein vitro activity of
methylene blue has been shown to translate into strong
gametocytocidal activity against P. falciparum in vivo
[11]. Primaquine has been reported to kill mature-stage
gametocytes, however, in this study primaquine showed
a 43% inhibition in ATP production but the in vivo
effect is likely to be much greater as it is thought that
one or more metabolites of primaquine are responsible
for its observed gametocytocidal activity in vivo [12]
Testing the activity of compounds against P. falci-
parum gametocytes is difficult both in vivo and in vitro.
An advantage of the in vitro testing described here is
that it allows compounds to be assessed in the absence
of confounding host factors but has the disadvantage
that it is not suitable for testing anti-folate drugs such
as sulphadoxine and proguanil, because the transgenic
parasite clone used in the study has altered sensitivity to
folate antagonists [4]. Pyrimethamine was tested as part
of this blinded study and as expected no reduction in
ATP production was seen. However, the creation of
Figure 1 A: The activity of a panel of currently used and experimental anti-malarial drugs against late stage Plasmodium falciparum
gametocytes. Bars with diagonal lines indicate compounds which resulted in a greater than 50% reduction in ATP production as compared to
the control. All drugs were tested at a concentration of 10 μM. B: IC50 values were determined for compounds which demonstrated a greater
than 50% reduction in ATP production.
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cassettes is possible and would overcome this limitation.
It is also feasible that some compounds may inhibit the
detection of ATP, resulting in false positives, so as with
all such assays additional orthogonal screening is still
recommended.
The relatively small number of compounds shown to
have significant anti-gametocyte activity in this study
highlights the lack of compounds with activity against
this important parasite life cycle stage and emphasizes
the need for continued research in this area.
Conclusion
T h i ss t u d yr e p o r t st h eu s eo fan o v e lin vitro assay to
test the activity of a panel of currently used and experi-
mental anti-malarial drugs against late stage P. falci-
parum gametocytes. Only eight out of 44 compounds
tested reduced gametocyte viability by at least 50%,
highlighting the need to develop novel compounds with
activity against this key life cycle stage. When used as
part of a screening programme the information provided
by this assay is a valuable first step, which can guide
future clinical studies.
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